1月9日，康华生物（维权）盘中上涨2.03%，截至14:00，报75.50元/股，成交1.60亿元，换手率1.83%， 总市值98.11亿元。 资金流向方面，主力资金净流出1036.66万元，特大单买入1331.02万元，占比8.30%，卖出2413.70万 元，占比15.04%；大单买入4601.70万元，占比28.68%，卖出4555.67万元，占比28.40%。 分红方面，康华生物A股上市后累计派现6.86亿元。近三年，累计派现4.62亿元。 机构持仓方面，截止2025年9月30日，康华生物十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股118.26万股，为新进股东。南方中证1000ETF（512100）位居第七大流通股东，持股85.06 万股，相比上期减少1.11万股。华夏行业景气混合A（003567）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，成都康华生物制品股份有限公司位于四川省成都经济技术开发区北京路182号，成立日期 2004年4月2日，上市日期2020年6月16日，公司主营业务涉及疫苗的综合性研究、开发、经营。主营业 务收入构成为：非免疫规划疫苗99.99%，其他0. ...

奥联电子所属申万行业为：汽车-汽车零部件-底盘与发动机系统。所属概念板块包括：生物医药、小米 汽车概念、动物疫苗、钙钛矿电池、专精特新等。 截至12月31日，奥联电子股东户数1.67万，较上期增加11.26%；人均流通股10236股，较上期减少 10.12%。2025年1月-9月，奥联电子实现营业收入3.24亿元，同比增长1.08%；归母净利润332.87万元， 同比增长235.88%。 分红方面，奥联电子A股上市后累计派现7034.23万元。近三年，累计派现598.89万元。 1月9日，奥联电子（维权）盘中上涨2.08%，截至10:51，报19.65元/股，成交1.09亿元，换手率3.31%， 总市值33.62亿元。 资金流向方面，主力资金净流入321.35万元，特大单买入155.86万元，占比1.43%，卖出369.06万元，占 比3.39%；大单买入2804.55万元，占比25.75%，卖出2270.00万元，占比20.84%。 奥联电子今年以来股价涨10.46%，近5个交易日涨10.46%，近20日跌0.51%，近60日涨13.26%。 资料显示，南京奥联汽车电子电器股份有限公司位于江苏省南京市江宁区 ...

市 场 研 究 [Table_Title] 万联晨会 [Table_MeetReportDate] 2025 年 12 月 25 日 星期四 [Table_Summary] 概览 核心观点 【市场回顾】 周三 A 股三大指数集体收涨，截止收盘，沪指收涨 0.53%，深成指收 涨 0.88%，创业板指收涨 0.77%。沪深两市成交额 18801.29 亿元。申 万行业方面，国防军工、电子、建筑材料领涨，农林牧渔、煤炭、食 品饮料领跌；概念板块方面，太赫兹、商业航天、同花顺果指数概念 涨幅居前，乳业、动物疫苗、猪肉概念跌幅居前。港股方面，恒生指 数收涨 0.17%，恒生科技指数收涨 0.19%；海外方面，美国三大指数 集体收涨，道指收涨 0.6%，标普 500 收涨 0.32%，纳指收涨 0.22%。 【重要新闻】 证 券 研 究 报 告 晨 会 纪 要 万千财富，与您相连 【国务院国资委：中央企业要加强上市公司质量和市值管理】中央企 业负责人会议 12 月 22 日至 23 日在京召开。国务院国资委党委书记、 主任张玉卓在会上表示，中央企业要坚持向内挖潜，做好全面预算管 理，加强全员、全要素、全生命周期成本管控 ...

资金流向方面，主力资金净流出1964.05万元，特大单买入0.00元，占比0.00%，卖出1785.97万元，占比 14.56%；大单买入2001.59万元，占比16.32%，卖出2179.67万元，占比17.77%。 天康生物今年以来股价涨12.32%，近5个交易日跌3.79%，近20日跌5.83%，近60日涨7.24%。 资料显示，天康生物股份有限公司位于新疆维吾尔自治区乌鲁木齐市高新区长春南路528号天康企业大 厦，成立日期2000年12月28日，上市日期2006年12月26日，公司主营业务涉及畜禽用生物疫苗、饲料及 饲用植物蛋白的生产、销售,种猪繁育、生猪养殖、屠宰加工及肉制品销售。主营业务收入构成为：生 猪养殖产业链收入32.20%，饲料收入27.51%，蛋白油脂加工收入16.37%，玉米收入14.75%，兽药收入 5.44%，其他收入3.40%，其他(补充)0.29%，担保费收入0.04%。 天康生物所属申万行业为：农林牧渔-饲料-畜禽饲料。所属概念板块包括：疫苗、宠物经济、动物疫 苗、猪肉概念、融资融券等。 12月1日，天康生物盘中下跌2.07%，截至13:29，报7.11元/股，成交1.23亿 ...

Core Viewpoint - The stock price of Pulaike has experienced fluctuations, with a recent decline of 2.03% and a year-to-date increase of 11.28% [1][2]. Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2]. - The revenue composition includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2]. Financial Performance - For the period from January to September 2025, Pulaike achieved operating revenue of 823 million yuan, representing a year-on-year growth of 8.04%. The net profit attributable to the parent company was 157 million yuan, reflecting a significant increase of 47.86% [2]. - Cumulative cash dividends since the A-share listing amount to 1.125 billion yuan, with 568 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders is 16,700, a decrease of 7.26% from the previous period. The average circulating shares per person increased by 7.83% to 20,739 shares [2]. - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF ranks sixth with 5.4716 million shares, an increase of 2.0217 million shares from the previous period. Hong Kong Central Clearing Limited is the eighth largest shareholder with 3.832 million shares, marking a new entry [3].

（文章来源：证券时报网） 资金流入比率方面，贤丰控股、罗牛山、亨通股份等流入比率居前，主力资金净流入率分别为 26.79%、13.84%、8.61%。（数据宝） 动物疫苗概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 000735 | 罗牛山 | 7.27 | 11.47 | 15688.56 | 13.84 | | 002141 | 贤丰控 | 10.00 | 11.16 | 12366.15 | 26.79 | | 600226 | 亨通股 | 3.99 | 3.26 | 3745.10 | 8.61 | | 600201 | 生物股 | 1.98 | 4.26 | 1521.20 | 2.61 | | 002688 | 金河生 | -0.65 | 1.21 | 173.05 | 3.10 | | 603718 | 海利生 | 0.00 | 0.78 | -95.73 | -2.77 | | 6880 ...

Core Insights - Hualan Vaccine's stock price decreased by 2.02% on November 20, trading at 22.34 CNY per share with a market capitalization of 13.43 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.63%, but a recent decline of 5.62% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Hualan Vaccine reported a revenue of 806 million CNY, a year-on-year decrease of 15.81%, and a net profit attributable to shareholders of 132 million CNY, down 50.51% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.037 billion CNY, with 957 million CNY distributed over the past three years [3] Shareholder Structure - As of October 20, 2025, the number of shareholders for Hualan Vaccine stands at 17,000, with an average of 35,332 circulating shares per person [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., which has reduced its holdings by 43,990 shares [3]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown significant growth this year, with an 81.11% increase in share price, indicating strong market performance and investor interest [1][2]. Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1]. - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1]. Financial Performance - For the period from January to September 2025, the company achieved an operating income of 1.042 billion yuan, representing a year-on-year growth of 7.38%. However, the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has distributed a total of 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.70% to 49,000, while the average circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai Zhongxin Livestock Breeding ETF, which holds 25.0398 million shares, and Hong Kong Central Clearing Limited, holding 21.1968 million shares, both showing increases in their holdings [3].

11月17日，温氏股份盘中下跌2.05%，截至09:55，报17.69元/股，成交2.44亿元，换手率0.23%，总市值 1177.08亿元。 分红方面，温氏股份A股上市后累计派现301.10亿元。近三年，累计派现69.35亿元。 资金流向方面，主力资金净流出1149.53万元，特大单买入702.43万元，占比2.88%，卖出1445.23万元， 占比5.93%；大单买入4298.48万元，占比17.63%，卖出4705.21万元，占比19.30%。 机构持仓方面，截止2025年9月30日，温氏股份十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股1.44亿股，相比上期增加550.13万股。易方达创业板ETF（159915）位居第九大流通股 东，持股1.13亿股，相比上期减少1909.10万股。 温氏股份今年以来股价涨10.48%，近5个交易日跌3.33%，近20日跌2.27%，近60日涨3.39%。 责任编辑：小浪快报 资料显示，温氏食品集团股份有限公司位于广东省云浮市新兴县新城镇东堤北路9号，成立日期1993年7 月26日，上市日期2015年11月2日，公司主营业务涉及肉鸡和肉猪养殖及其产品销 ...

Company Overview - KQ Bio, established on January 11, 2001, and listed on September 22, 2020, is located in Wuhan, Hubei Province. The company specializes in the research, production, and sales of veterinary biological products and animal epidemic prevention technology services [1][2]. - The main business revenue composition includes 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - For the period from January to September 2025, KQ Bio achieved a revenue of 738 million yuan, representing a year-on-year growth of 10.87%. The net profit attributable to the parent company was 338 million yuan, showing a year-on-year increase of 29.62% [2]. - Cumulative cash dividends since the A-share listing amount to 711 million yuan, with 488 million yuan distributed over the past three years [3]. Stock Performance - As of November 17, KQ Bio's stock price was 16.24 yuan per share, with a market capitalization of 7.57 billion yuan. The stock has increased by 17.15% year-to-date but has seen a decline of 0.43% over the last five trading days, 6.13% over the last 20 days, and 5.80% over the last 60 days [1]. - The number of shareholders as of September 30 was 9,713, an increase of 2.41% from the previous period, while the average circulating shares per person decreased by 2.36% to 47,990 shares [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 5.5731 million shares, an increase of 3.2155 million shares from the previous period [3].